Hyperhomocysteinemia in L-dopa treated patients with Parkinson's Disease: Potential implications in cognitive dysfunction and dementia?

Current Medicinal Chemistry

Volumn 17, Issue 28, 2010, Pages 3253-3261

  Zoccolella, S ^a   Lamberti, S V ^b   Iliceto, G ^b   Santamato, A ^a   Lamberti, P ^b   Logroscino, G ^b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Cognitive dysfunctions; Dementia; Homocysteine; L dopa; Parkinson's Disease

Indexed keywords

HOMOCYSTEINE; LEVODOPA; ANTIPARKINSON AGENT;

COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; HUMAN; HYPERHOMOCYSTEINEMIA; NERVE DEGENERATION; PARKINSON DISEASE; REVIEW; METABOLISM; NERVE CELL; PATHOLOGY;

ANTIPARKINSON AGENTS; COGNITION DISORDERS; DEMENTIA; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LEVODOPA; NEURONS; PARKINSON DISEASE;

EID: 79952200967     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986710792232012     Document Type: Review

References (65)

1. Mattson, M. P.; Shea, T. B. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci., 2003, 26, 137-146. (Pubitemid 36183675)
2. Stanger, O.; Herrmann, W.; Pietrzik, K.; Fowler, B.; Geisel, J.; Dierkes, J.; Weger, M.; DACH-LIGA Homocystein e. V. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin. Chem. Lab. Med., 2003, 41, 1392-1403. (Pubitemid 37493551)
3. Selley, M. L.; Close, D. R.; Stern, S. E. The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol. Aging., 2002, 23, 383-388. (Pubitemid 34312021)
4. Finkelstein, J. D. The metabolism of homocysteine:pathways and regulaion. Eur. J. Pediatr., 1998, 157, S40-S44.
5. Morris, M. S. Homocysteine and Alzheimer's disease. Lancet Neurol., 2003, 2, 425-428. (Pubitemid 36793935)
6. Quadri, P.; Fragiacomo, C.; Pezzati, R.; Zanda, E.; Forloni, G.; Tettamanti, M.; Lucca, U. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am. J. Clin. Nutr., 2004, 80, 114-122. (Pubitemid 41115564)
7. Seshadri, S.; Beiser, A.; Selhub, J.; Jacques, P. F.; Rosenberg, I. H.; D'Agostino, R. B.; Wilson, P. W.; Wolf, P. A. Plasma Homocysteine as a risk factor for dementia and Alzheimer's Disease. N. Engl. J. Med., 2002, 346, 476-483. (Pubitemid 34441738)
8. Robert, K.; Pagès, C.; Ledru, A.; Delabar, J.; Caboche, J.; Janel, N. Regulation of extracellular signal-regulated kinase by homocysteine in hippocampus. Neuroscience, 2005, 133, 925-935. (Pubitemid 40814601)
9. Tjattas, L.; Ortiz, D. O.; Dhivant, S.; Mitton, K.; Rogers, E.; Shea, T. B. Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation. Aging Cell, 2004, 3, 71-76. (Pubitemid 40246667)
10. Jara-Prado, A.; Ortega-Vazquez, A.; Martinez-Ruano, L.; Rios, C.; Santamaria, A. Homocysteine-induced brain lipid peroxidation: effects of NMDA receptor blockade, antioxidant treatment, and nitric oxide synthase inhibition. Neurotox. Res., 2003, 5, 237-243.
11. Kruman, I. I.; Culmsee, C.; Chan, S. L.; Kruman, Y.; Guo, Z.; Penix, L.; Mattson, M. P. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J. Neurosci., 2000, 20, 6920-6926.
12. Marsden, C. D. Basal ganglia disease. Lancet, 1982, 2, 1141-1147.
13. Chaudhuri, K. R.; Healy, D. G.; Schapira, A. H. National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol., 2006, 5, 235-245. (Pubitemid 43238347)
14. Caballo, N.; Martí, M. J.; Tolosa, E. Cognitive dysfunction and dementia in Parkinson disease. Mov. Disord., 2007, 22(Suppl 17), S358-S366. (Pubitemid 350134189)
15. Hely, M. A.; Wayne, G. J.; Reid, W. G.; Halliday, G. M.; Morris, J. G. The Sydney Multicenter Study of Parkinson's Disease: the inevitability of dementia at 20 years. Mov. Disord., 2008, 23, 837-844.
16. Zoccolella, S.; Martino, D.; Defazio, G.; Lamberti, P.; Livrea, P. Hyperhomocysteinemia in movement disorders: Current evidence and hypotheses. Curr. Vasc. Pharmacol., 2006, 4, 237-243. (Pubitemid 46785491)
17. Postuma, R. B.; Lang, A. Homocysteine and levodopa. Should parkinson disease patients receive preventative therapy? Neurology, 2004, 63, 886-891. (Pubitemid 39297652)
18. O'Suilleabhain, P. E.; Diaz-Arrastia, R. Levodopa elevates homocysteine: is this a problem? Arch. Neurol., 2004, 61, 633-634. (Pubitemid 38637676)
19. Irizarry, M. C.; Gurol, M. E.; Raju, S.; Diaz-Arrastia, R.; Locascio, J. J.; Tennis, M.; Hyman, B. T.; Growdon, J. H.; Greenberg, S. M.; Bottiglieri, T. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology, 2005, 65, 1402-1408. (Pubitemid 41552769)
20. O'Suilleabhain, P. E.; Sung, V.; Hernandez, C.; Lacritz, L.; Dewey, R. B. Jr.; Bottiglieri, T.; Diaz-Arrastia, R. Elevated Plasma Homocysteine Level in Patients With Parkinson Disease: Motor, Affective, and Cognitive Associations. Arch. Neurol., 2004, 61, 865-868. (Pubitemid 38747325)
21. Zoccolella, S.; Lamberti, P.; Iliceto, G.; Diroma, C.; Armenise, E.; Defazio, G.; Lamberti, S. V.; Fraddosio, A,; de Mari, M.; Livrea, P. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clin. Chem. Lab. Med., 2005, 43, 1107-1110. (Pubitemid 41581969)
22. O'Suilleabhain, P. E.; Oberle, R.; Bartis, C.; Dewey, R. B. Jr.; Bottiglieri, T.; Diaz-Arrastia, R. Clinical course in Parkinson's disease with elevated homocysteine. Parkinsonism Relat. Disord., 2006, 12, 103-107. (Pubitemid 43234311)
23. Ozer, F.; Meral, H.; Hanoglu, L.; Aydemir, T.; Yilsen, M.; Cetin, S.; Ozturk, O.; Seval, H.; Koldas, M. Plasma Homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurol. Res., 2006, 28, 853-858. (Pubitemid 44904462)
24. Camicioli, R. M.; Bouchard, T. P.; Somerville, M. J. Homocysteine is not associated with global motor or cognitive measures in nondemented older parkinson's disease patients. Mov. Disord., 2009, 24, 176-182.
25. Hassin-Baer, S.; Cohen, O.; Vakil, E.; Sela, B. A.; Nitsan, Z.; Schwartz, R.; Chapman, J.; Tanne, D. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin. Neuropharmacol., 2006, 29, 305-311. (Pubitemid 44729941)
26. Stathis, P.; Kiebardis, A.; Kiosterakis, G.; Bournousouzis, N.; Karakasis, P.; Fytou-Pallikari, A.; Kalkani, E.; Maltezou, M. Serum homocysteine concentrations and cognitive decline in Parkinson's disease patients: a controlled study. Mov. Disord., 2006, 21(Suppl 15), S566-567.
27. Nakaso, K.; Yasui, K.; Kowa, H.; Kitayama, M.; Kusumi, M.; Takeshima, T.; Nakashima, K. Hyperhomocysteinemia: a predictive parameter for disease progression due to non-motor complications in Parkinson's disease. Mov. Disord., 2006, 21(Suppl 15), S488-489.
28. Shin, H.; Sohn, Y. H. Role of homocysteine in developing cognitive dysfunction in parkinson disease; comparison with Alzheimer disease. Mov. Disord., 2006, 21(Suppl 15), S470.
29. Rodriguez-Oroz, M. C.; Lage, P. M., Sanchez-Mut, J.; Lamet I., Pagonabarraga, J.; Toledo, J. B.; García-Garcia, D.; Clavero, P.; Samaranch, L.; Irurzun, C.; Matsubara, J. M.; Irigoien, J.; Bescos, E.; Kulisevsky, J.; Pérez-Tur, J.; Obeso, J. A. Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study. Mov. Disord., 2009, 24, 1437-44.
30. Zoccolella, S.; dell'Aquila, C.; Abruzzese, G.; Antonini, A.; Bonuccelli, U.; Canesi, M.; Cristina, S.; Marchese, R.; Pacchetti, C.; Zagaglia, R.; Logroscino, G.; Defazio, G.; Lamberti, P.; Livrea, P. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. Mov. Disord., 2009, 24, 1028-1033.
31. Litvinenko, I. V.; Odinak, M. M.; Pozdnyakov, A. V.; Mogilnaya, V. I.; Shatova, A. V. Plasma homocysteine level correlate with white matter brain lesions and cognitive impairment in Parkinson's disease. Eur. J. Neurol., 2005, 12(Suppl 2), S100.
32. Menendez, M.; Ribacoba, R.; Jimenez, G.; Virgili, J. R.; Huerta, C.; de la Vega, V. Dementia and hyperhomocysteinemia in Parkinson's disease. Mov. Disord., 2007, 22(Suppl 16), S186.
33. Barone, P.; Burn, D. J.; van Laar, T.; Hsu, C.; Poewe, W.; Lane, R. M. Rivastigmine versus placebo in hyperhomocysteinemic parkinson's disease dementia patients. Mov. Disord., 2008, 23, 1532-1540.
34. Obeid, R.; Schadt, A.; Dillmann, U.; Kostopoulos, P.; Fassbender, K.; Herrmann, W. Methylation Status and Neurodegenerative Markers in Parkinson Disease. Clin. Chem., 2009, 55, 1852-60.
35. Galvin, J. E. Cognitive change in Parkinson disease. Alzheimer Dis. Assoc. Disord., 2006, 20, 302-310. (Pubitemid 44900947)
36. Morris, M. S. Homocysteine and Alzheimer's disease. Lancet Neurol, 2003, 2, 425-428. (Pubitemid 36793935)
37. Lippa, C. F.; Duda, J. E.; Grossman, M.; Hurtig, H. I.; Aarsland, D.; Boeve, B. F.; Brooks, D. J.; Dickson, D. W.; Dubois, B.; Emre, M.; Fahn, S.; Farmer, J. M.; Galasko, D.; Galvin, J. E.; Goetz, C. G.; Growdon, J. H.; Gwinn-Hardy, K. A.; Hardy, J.; Heutink, P.; Iwatsubo, T.; Kosaka, K.; Lee, V. M.; Leverenz, J. B.; Masliah, E.; McKeith, I. G.; Nussbaum, R. L.; Olanow, C. W.; Ravina, B. M.; Singleton, A. B.; Tanner, CM.; Trojanowski, J. Q.; Wszolek, Z. K. DLB/PDD Working Group. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology, 2007, 68, 812-819. (Pubitemid 46568532)
38. Emre, M. Treatment of dementia associated with Parkinson's disease. Parkinsonism Relat. Disord., 2007, 13 Suppl 3, S457-461. (Pubitemid 351215286)
39. Vigneswara, V.; Lowenson, J. D.; Powell, CD.; Thakur, M.; Bailey, K.; Clarke, S.; Ray, D. E.; Carter, W. G. Proteomic identification of novel substrates of a protein isoaspartyl methyltransferase repair enzyme. J. Biol. Chem., 2006, 281, 32619-32629. (Pubitemid 46036817)
40. Bönsch, D.; Reulbach, U.; Bayerlein, K.; Hillemacher, T.; Kornhuber, J.; Bleich, S. Elevated alpha synuclein mRNA levels are associated with craving in patients with alcoholism. Biol. Psychiatry., 2004, 56, 984-986. (Pubitemid 39643058)
41. Slodzinski, H.; Moran, L. B.; Michael, G. J.; Wang, B.; Novoselov, S.; Cheetham, M. E.; Pearce, R. K. B.; Graeber, M. B. Homocysteineinduced endoplasmic reticulum protein (herp) is up-regulated in parkinsonian substantia nigra and present in the core of Lewy bodies. Clin. Neuropathol, 2009, 28, 333-343.
42. Vermeer, S. E.; Prinds, N. D.; den Hejer, T.; Hofman, A.; Koudstaal, P. J.; Breteler, M. M. Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med., 2003, 348, 1215-1222. (Pubitemid 36359297)
43. den Heijer, T.; Vermeer, S. E.; Clarke, R.; Oudkerk, M.; Koudstaal, P. J.; Hofman, A.; Breteler, M. M. Homocysteine and brain atrophy on MRI of non demented elderly. Brain, 2003, 126, 170-175. (Pubitemid 36068567)
44. Obeid, R.; Herrmann, W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett., 2006, 580, 2994-3005. (Pubitemid 43744523)
45. Aarsland, D.; Beyer, M. K.; Kurz, M. W. Dementia in Parkinson's disease. Curr. Opin. Neurol, 2008, 21, 676-682.
46. Seshadri, S.; Wolf P. A. Homocysteine and the brain: vascular risk factor or neurotoxin? Lancet Neurol, 2003, 2:11. (Pubitemid 37443337)
47. Perla-Kaján, J.; Twardowski, T.; Jakubowski, H. Mechanisms of homocysteine toxicity in humans. Amino Acids, 2007, 32, 561-572. (Pubitemid 46790938)
48. Kamath, A. F.; Chauhan, A. K.; Kisucka, J.; Dole, V. S.; Loscalzo, J.; Handy, D. E.; Wagner, D. D. Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. Blood, 2006, 107, 591-593. (Pubitemid 43090794)
49. Braak, H.; Braak, E.; Yilmazer, D.; de Vos, R. A.; Jansen, E. N.; Bohl, J. New aspects of pathology in Parkinson's disease with concomitant incipient Alzheimer's disease. J. Neural. Transm. Suppl, 1996, 48, 1-6. (Pubitemid 26423342)
50. Sai, X.; Kawamura, Y.; Kokame, K.; Yamaguchi, H.; Shiraishi, H.; Suzuki, R.; Suzuki, T.; Kawaichi, M.; Miyata, T.; Kitamura, T.; De Strooper, B.; Yanagisawa, K.; Komano, H. Endoplasmic reticulum stress-inducible protein, Herp, enhances presenilin-mediated generation of amyloid beta-protein. J. Biol. Chem., 2002, 277, 12915-12920. (Pubitemid 34952658)
51. Obeid, R.; Kasoha, M.; Knapp, J. P.; Kostopoulos, P.; Becker, G.; Fassbender, K.; Herrmann, W. Folate and methylation status in relation to phosphorylated tau protein (181P) and beta-amyloid (1-42) in cerebrospinal fluid. Clin. Chem., 2007, 53, 1129-1136. (Pubitemid 46867531)
52. Braak, H.; Del Tredici, K.; Rüb, U.; de Vos, R. A.; Jansen Steur, E. N.; Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging, 2003, 24, 197-211. (Pubitemid 36007810)
53. Perry, E. K.; Curtis, M.; Dick, D. J.; Candy, J. M.; Atack, J. R.; Bloxham, C. A.; Blessed, G.; Fairbairn, A.; Tomlinson, B. E.; Perry, R. H. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 1985, 48, 413-421. (Pubitemid 15064881)
54. Tiraboschi, P.; Hansen, L. A.; Alford, M.; Sabbagh, M. N.; Schoos, B.; Masliah, E.; Thal, L. J.; Corey-Bloom, J. Cholinergic dysfunction in diseases with Lewy bodies. Neurology., 2000, 54, 407-411. (Pubitemid 30078073)
55. Bohnen, N. I.; Kaufer, D. I.; Ivanco, L. S.; Lopresti, B.; Koeppe, R. A.; Davis, J. G.; Mathis, C. A.; Moore, R. Y.; DeKosky, S. T. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol., 2003, 60, 1745-1748. (Pubitemid 37521630)
56. Darvesh, S.; Walsh, R.; Martin, E. Homocysteine thiolactone and human cholinesterases. Cell. Mol. Neurobiol., 2007, 27, 33-48. (Pubitemid 46169893)
57. Müller, T.; Werne, B.; Fowler, B.; Kuhn, W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet., 1999, 354, 126-127. (Pubitemid 29313150)
58. Nakaso, K.; Yasui, K.; Kowa, H.; Kusumi, M.; Ueda, K.; Yoshimoto, Y.; Takeshima, T.; Sasaki, K.; Nakashima, K. Hypertrophy of IMC of carotid artery in Parkinson's Disease is associated with levodopa, homocysteine and MTHFR genotype. J. Neurol. Sci., 2003, 207, 19-23. (Pubitemid 36287098)
59. Rogers, J. D.; Sanchez-Saffon, A.; Frol, A. B.; Diaz-Arrastia, R. Elevated plasma homocysteine levels in patients treated with Levodopa. Arch. Neurol., 2003, 60, 59-64.
60. Cruickshank, J. M.; Neil-Dwyer, G.; Dorrance, D. E.; Hayes, Y.; Patel, S. Acute effects of smoking on blood pressure and cerebral blood flow. J. Hum. Hypertens., 1989, 3, 443-449. (Pubitemid 20033327)
61. Cataldo, J. K.; Prochaska, J. J.; Glantz, S. A. Cigarette smoking is a risk factor for Alzheimer's Disease: an analysis controlling for tobacco industry affiliation. J. Alzheimers Dis., 2010, 19, 465-480.
62. Zoccolella, S.; Iliceto, G.; deMari, M.; Livrea, P.; Lamberti, P. Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review. Clin. Chem. Lab. Med., 2007, 45, 1607-1613. (Pubitemid 350232965)
63. Tangney, C. C.; Tang, Y.; Evans, D. A.; Morris, M. C. Biochemical indicators of vitamin B12 and folate insufficiency and cognitive decline. Neurology, 2009, 72, 361-367.
64. Viswanathan, A.; Raj, S.; Greenberg, S. M.; Stampfer, M.; Campbell, S.; Hyman, B. T.; Irizarry, M. C. Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology, 2009, 72, 268-272.
65. Flicker, L.; Martins, R. N.; Thomas, J.; Acres, J.; Taddei, K.; Vasikaran, S. D.; Norman, P.; Jamrozik, K.; Almeida, O. P. B-vitamins reduce plasma levels of beta amyloid. Neurobiol. Aging, 2008, 29, 303-305.